AU2005205066C1 - The use of quaternary pyridinium salts as vasoprotective agents - Google Patents

The use of quaternary pyridinium salts as vasoprotective agents Download PDF

Info

Publication number
AU2005205066C1
AU2005205066C1 AU2005205066A AU2005205066A AU2005205066C1 AU 2005205066 C1 AU2005205066 C1 AU 2005205066C1 AU 2005205066 A AU2005205066 A AU 2005205066A AU 2005205066 A AU2005205066 A AU 2005205066A AU 2005205066 C1 AU2005205066 C1 AU 2005205066C1
Authority
AU
Australia
Prior art keywords
disease
condition
use according
hypercholesterolemia
atherosclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2005205066A
Other languages
English (en)
Other versions
AU2005205066B2 (en
AU2005205066A1 (en
Inventor
Stefan Chlopicki
Jerzy Gebicki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmena SA
Original Assignee
Pharmena SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmena SA filed Critical Pharmena SA
Publication of AU2005205066A1 publication Critical patent/AU2005205066A1/en
Assigned to PHARMENA SA reassignment PHARMENA SA Alteration of Name(s) of Applicant(s) under S113 Assignors: PHARMENA SP Z O.O.
Publication of AU2005205066B2 publication Critical patent/AU2005205066B2/en
Application granted granted Critical
Publication of AU2005205066C1 publication Critical patent/AU2005205066C1/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Physiology (AREA)
  • Surgery (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
AU2005205066A 2004-01-12 2005-01-07 The use of quaternary pyridinium salts as vasoprotective agents Expired AU2005205066C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PLP-364348 2004-01-12
PL04364348A PL364348A1 (en) 2004-01-12 2004-01-12 Application of quaternary pyridine salts as vessel protection agent
PCT/EP2005/050057 WO2005067927A2 (en) 2004-01-12 2005-01-07 The use of quaternary pyridinium salts as vasoprotective agents

Publications (3)

Publication Number Publication Date
AU2005205066A1 AU2005205066A1 (en) 2005-07-28
AU2005205066B2 AU2005205066B2 (en) 2010-04-29
AU2005205066C1 true AU2005205066C1 (en) 2010-08-26

Family

ID=34793495

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005205066A Expired AU2005205066C1 (en) 2004-01-12 2005-01-07 The use of quaternary pyridinium salts as vasoprotective agents

Country Status (13)

Country Link
US (6) US7935717B2 (enExample)
EP (2) EP2279738A1 (enExample)
JP (2) JP5052138B2 (enExample)
CN (1) CN1905875B (enExample)
AT (1) ATE524179T1 (enExample)
AU (1) AU2005205066C1 (enExample)
CA (1) CA2547234C (enExample)
DK (1) DK1713480T3 (enExample)
ES (1) ES2372756T3 (enExample)
PL (2) PL364348A1 (enExample)
PT (1) PT1713480E (enExample)
RU (1) RU2366420C2 (enExample)
WO (1) WO2005067927A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL364348A1 (en) 2004-01-12 2005-07-25 PHARMENA Sp.z o.o. Application of quaternary pyridine salts as vessel protection agent
AU2006329564A1 (en) 2005-07-11 2007-07-05 Pharmena North America Inc. Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative
EP1963270B1 (en) * 2005-12-09 2009-08-05 Cerecon AG Quaternary 3 -amido, n-methylpyridinium salts as anti -inflammatory agents
CA2657606A1 (en) 2006-03-08 2007-09-13 Cortria Corporation Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries
CA2700585A1 (en) * 2006-10-18 2008-08-14 Dermena North America, Inc. Food extracts for treatment of lipoprotein abnormalities and skin diseases and skin disorders
PL381862A1 (pl) 2007-02-28 2008-09-01 Trigendo Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie związków pirydyniowych i sposób leczenia
WO2009042440A1 (en) * 2007-09-28 2009-04-02 Cortria Corporation 1-methyl nicotinamide and derivatives for treatment of gastric injury
PL2211858T3 (pl) 2007-10-12 2015-06-30 Politechnika Lodzka Zastosowanie czwartorzędowych soli pirydyniowych do hamowania przerzutów nowotworowych
US8304439B1 (en) 2007-10-12 2012-11-06 Politechnika Lodzka Use of quaternary pyridinium salts as a therapeutic or preventing agent against ionizing radiation-induced damage
WO2009047290A1 (en) * 2007-10-12 2009-04-16 Politechnika Lodzka Use of quaternary pyridinium salts for radioprotection
US20110263659A1 (en) * 2008-05-06 2011-10-27 Cortria Corporation Analogs of 1-Methylnicotinamide
WO2010000673A1 (en) * 2008-07-01 2010-01-07 Politechnika Lódzka N'-nitroxyalkylnicotinamides for the treatment of cardiovascular diseases
US8575175B2 (en) 2008-07-23 2013-11-05 Toray Industries, Inc. Therapeutic agent for chronic renal failure
EP2186419A1 (en) * 2008-11-13 2010-05-19 Tchibo GmbH NMP-containing extract, a method of its production and uses thereof
RU2425672C1 (ru) * 2010-04-12 2011-08-10 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ коррекции гипергомоцистеин-индуцированной эндотелиальной дисфункции смесью растворов гомеопатических разведений поликлональных кроличьих антител к эндотелиальной синтазе оксида азота человека - с12, с30, с200
KR101309576B1 (ko) * 2011-05-25 2013-09-17 연세대학교 산학협력단 대사물질을 이용한 심부전 바이오마커
PL226999B1 (pl) * 2013-06-11 2017-10-31 Univ Jagiellonski Azotan (III) 3 -karbamoilo -1-metylopirydyniowy, sposób jego otrzymywania izastosowanie
CN105771005A (zh) * 2016-03-24 2016-07-20 乐普（北京）医疗器械股份有限公司 一种抗风湿性血管狭窄药物支架及其制备方法和应用
WO2018015862A1 (en) 2016-07-18 2018-01-25 Pharmena S.A. 1-methylnicotinamide salts for use in raising the blood levels of adiponectin
ES2967074T3 (es) * 2016-07-18 2024-04-25 Pharmena S A 1 metilnicotinamida para el tratamiento de una enfermedad cardiovascular
CN118221546A (zh) * 2017-07-27 2024-06-21 密歇根大学董事会 纤维蛋白溶酶原活化物抑制因子-1（pai-1）抑制剂和使用方法
PL238932B1 (pl) * 2017-12-31 2021-10-18 Univ Jagiellonski Pochodne soli pirydyniowych oraz ich zastosowanie
PH12021551394B1 (en) * 2019-01-02 2024-04-26 Celagenex Res India Pvt Ltd Potent synergistic compositions of vasoactive mediators enhancers for improving vascular endothelial function
WO2021205341A1 (en) 2020-04-07 2021-10-14 Pharmena S.A. 1-methylnicotinamide for the prevention/treatment of inflammatory airway diseases
EP4213821A2 (en) * 2020-09-21 2023-07-26 The Regents of the University of California Immunological effects of metabolites
CN115837023B (zh) * 2023-02-20 2023-05-16 中山大学附属第八医院（深圳福田） 1-甲基烟酰胺在制备抗血管钙化药物中的应用
US20240350475A1 (en) * 2023-04-13 2024-10-24 University Of South Carolina Trigonelline mitigates cardiomyopathy caused by sars-cov-2 spike protein under obesity
PL447656A1 (pl) * 2024-01-31 2025-08-04 Politechnika Poznańska Nowe czwartorzędowe sole amoniowe zawierające anion pochodzący od kwasu nikotynowego oraz kation N-alkilonikotynamidowy, sposób ich otrzymywania oraz zastosowanie jako substancje o aktywności przeciwbakteryjnej
PL248942B1 (pl) * 2024-01-31 2026-02-16 Politechnika Poznanska Czwartorzędowe sole amoniowe zawierające anion 2-furanokarboksylanowy i kation będący alkilową pochodną nikotynamidu, sposób ich otrzymywania i zastosowanie jako środki myjąco-dezynfekujące
PL449092A1 (pl) * 2024-07-01 2026-01-05 Uniwersytet Jagielloński Synergiczna kombinacja 1-metylonikotynamidu (MNA) i witaminy K do zastosowania w leczeniu lub zapobieganiu powikłaniom sercowo-naczyniowym terapii przeciwnowotworowych
PL450543A1 (pl) * 2024-12-11 2026-06-15 Politechnika Poznańska Czwartorzędowe sole amoniowe z kationem 3-karbamoilo-1-alkilopirydyniowym i anionem (R)-migdalanowym, sposób ich otrzymywania oraz zastosowanie jako substancje o aktywności przeciwbakteryjnej
PL450542A1 (pl) * 2024-12-11 2026-06-15 Politechnika Poznańska Czwartorzędowe sole amoniowe zawierające kation 3-karbamoiIo-1-alkilopirydyniowy i anion 4- aminobenzoesanowy, sposób ich otrzymywania i zastosowanie jako środki bakteriobójcze
PL450544A1 (pl) * 2024-12-11 2026-06-15 Politechnika Poznańska Czwartorzędowe sole amoniowe z kationem 3-karbamoilo-1-alkilopirydyniowym i anionem (S)-migdalanowym, sposób ich otrzymywania oraz zastosowanie jako substancje o aktywności przeciwbakteryjnej
PL452423A1 (pl) * 2025-06-20 2026-08-03 Politechnika Poznańska Sposób określania właściwości przeciwzapalnych czwartorzędowych soli amoniowych zawierających kation 3-karbamoilo-1-alkilopirydyniowy i anion 4-aminobenzoesanowy z użyciem albuminy jaja kurzego
PL452422A1 (pl) * 2025-06-20 2026-08-03 Politechnika Poznańska Sposób określania właściwości przeciwzapalnych czwartorzędowych soli amoniowych zawierających anion pochodzący od kwasu nikotynowego oraz kation N-alkilonikotynamidowy z użyciem albuminy jaja kurzego

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE840698C (de) * 1949-07-12 1952-06-05 Cilag Aktiengesellschaft Verfahren zur herstellung neuer derivate des nicotinsaureamids

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB675430A (en) 1949-07-12 1952-07-09 Cilag Ltd Novel quaternary nicotinic acid amide derivatives and production thereof
US5260305A (en) * 1988-12-12 1993-11-09 E. R. Squibb & Sons, Inc. Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US6746691B2 (en) * 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6676967B1 (en) * 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6818229B1 (en) * 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6406715B1 (en) * 1993-09-20 2002-06-18 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles
US6129930A (en) * 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US20030161880A1 (en) * 1997-03-06 2003-08-28 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
US6469035B1 (en) * 1997-07-31 2002-10-22 Eugenio A. Cefali Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
IE970731A1 (en) * 1997-10-07 2000-10-04 Fuisz Internat Ltd Product and method for the treatment of hyperlipidemia
PL190755B1 (pl) * 1999-01-07 2006-01-31 Pharmena Sp Z Oo Preparat do leczenia i profilaktyki chorób skóry
JP2002255846A (ja) * 2001-02-26 2002-09-11 Sunstar Inc 経口組成物
US20050130990A1 (en) * 2001-03-23 2005-06-16 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
CA2341952A1 (en) * 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
US8039459B2 (en) * 2004-07-15 2011-10-18 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US7153870B2 (en) * 2003-07-25 2006-12-26 Pfizer Inc. Nicotinamide derivatives useful as PDE4 inhibitors
PL364348A1 (en) 2004-01-12 2005-07-25 PHARMENA Sp.z o.o. Application of quaternary pyridine salts as vessel protection agent
EP1811996A1 (en) 2004-11-05 2007-08-01 Arena Pharmaceuticals, Inc. Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists
AU2006329564A1 (en) 2005-07-11 2007-07-05 Pharmena North America Inc. Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative
CA2700585A1 (en) 2006-10-18 2008-08-14 Dermena North America, Inc. Food extracts for treatment of lipoprotein abnormalities and skin diseases and skin disorders
PL381862A1 (pl) * 2007-02-28 2008-09-01 Trigendo Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie związków pirydyniowych i sposób leczenia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE840698C (de) * 1949-07-12 1952-06-05 Cilag Aktiengesellschaft Verfahren zur herstellung neuer derivate des nicotinsaureamids

Also Published As

Publication number Publication date
WO2005067927A2 (en) 2005-07-28
CA2547234A1 (en) 2005-07-28
US8124631B2 (en) 2012-02-28
RU2006129299A (ru) 2008-02-20
US9333196B2 (en) 2016-05-10
JP5052138B2 (ja) 2012-10-17
WO2005067927A3 (en) 2005-12-01
EP2279738A1 (en) 2011-02-02
US20160346265A1 (en) 2016-12-01
ES2372756T3 (es) 2012-01-26
JP2007517833A (ja) 2007-07-05
CN1905875B (zh) 2010-07-28
US9119844B2 (en) 2015-09-01
AU2005205066B2 (en) 2010-04-29
JP5597179B2 (ja) 2014-10-01
EP1713480B1 (en) 2011-09-14
US20110245297A1 (en) 2011-10-06
EP1713480A2 (en) 2006-10-25
US20080207702A1 (en) 2008-08-28
US20140296305A1 (en) 2014-10-02
PL364348A1 (en) 2005-07-25
ATE524179T1 (de) 2011-09-15
CN1905875A (zh) 2007-01-31
PL1713480T3 (pl) 2011-12-30
US9675601B2 (en) 2017-06-13
US20100173956A1 (en) 2010-07-08
US7935717B2 (en) 2011-05-03
US20150133508A1 (en) 2015-05-14
CA2547234C (en) 2010-07-20
DK1713480T3 (da) 2012-01-16
RU2366420C2 (ru) 2009-09-10
AU2005205066A1 (en) 2005-07-28
US8969391B2 (en) 2015-03-03
JP2012072150A (ja) 2012-04-12
PT1713480E (pt) 2011-11-28

Similar Documents

Publication Publication Date Title
AU2005205066B2 (en) The use of quaternary pyridinium salts as vasoprotective agents
US20020094996A1 (en) Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases
RU2477132C2 (ru) Применение четвертичных соединений пиридиния для вазопротекции и/или гепатопротекции
US20060148763A1 (en) Compounds and methods for regulating triglyceride levels
CA2373296C (en) Combination of nicotinic acid or nicotinamide with riboflavin for the treatment of pruritus, itching and inflammation disorders
Schram et al. The effect of calcium dobesilate on vascular endothelial function, blood pressure, and markers of oxidation in obese male smokers: a placebo-controlled randomised clinical trial
MXPA06007930A (en) The use of quaternary pyridinium salts as vasoprotective agents
Ballabeni et al. Effects of subacute treatment with benzopyranopyrimidines in hemostasis and experimental thrombosis in mice
JP2025504447A (ja) アスピリン及びその他のｎｓａｉｄの高透過プロドラッグによる心血管疾患の予防又は治療
US5455257A (en) Lacidipine for the treatment of arteriosclerosis
Whayne Coronary atherosclerosis, low-density lipoproteins and markers of thrombosis, inflammation and endothelial dysfunction
JP2001011083A (ja) ビス（ハロゲンピコリネート）オキソバナジウム
TW205542B (enExample)
KR20070102694A (ko) 혈당 강하제를 함유하는, 내당능 이상, 경계형 당뇨병,인슐린 저항성 및 고인슐린혈증 개선 또는 치료용 의약조성물
Bashour Dilantin: experimental studies and clinical uses
Mallarkey et al. Livostin-generic name: levocabastine

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 APR 2010.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 APR 2010

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired